SG11201802773RA - Methods of making fucosylated and afucosylated forms of a protein - Google Patents

Methods of making fucosylated and afucosylated forms of a protein

Info

Publication number
SG11201802773RA
SG11201802773RA SG11201802773RA SG11201802773RA SG11201802773RA SG 11201802773R A SG11201802773R A SG 11201802773RA SG 11201802773R A SG11201802773R A SG 11201802773RA SG 11201802773R A SG11201802773R A SG 11201802773RA SG 11201802773R A SG11201802773R A SG 11201802773RA
Authority
SG
Singapore
Prior art keywords
fucosylated
protein
making
methods
afucosylated forms
Prior art date
Application number
SG11201802773RA
Inventor
Shahram Misaghi
John B Lowe
Bradley R Snedecor
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201802773RA publication Critical patent/SG11201802773RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
SG11201802773RA 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein SG11201802773RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249828P 2015-11-02 2015-11-02
US201662338280P 2016-05-18 2016-05-18
PCT/US2016/059922 WO2017079165A1 (en) 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein

Publications (1)

Publication Number Publication Date
SG11201802773RA true SG11201802773RA (en) 2018-05-30

Family

ID=57326491

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201802773RA SG11201802773RA (en) 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein
SG10202103875WA SG10202103875WA (en) 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202103875WA SG10202103875WA (en) 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein

Country Status (14)

Country Link
US (2) US10975168B2 (en)
EP (2) EP3925970A1 (en)
JP (1) JP6983772B2 (en)
KR (1) KR20180068967A (en)
CN (2) CN116731147A (en)
AU (2) AU2016350732A1 (en)
BR (1) BR112018007356A2 (en)
CA (1) CA2999047A1 (en)
ES (1) ES2875274T3 (en)
IL (1) IL258161B2 (en)
MX (1) MX2018004831A (en)
PL (1) PL3371206T3 (en)
SG (2) SG11201802773RA (en)
WO (1) WO2017079165A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
CA3010598A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
CN110945028B (en) 2017-07-10 2023-09-08 国际药物发展生物技术公司 Treatment of B cell malignancies with non-fucosylated pro-apoptotic anti-CD 19 antibodies in combination with anti-CD 20 antibodies or chemotherapeutic agents
EA202092286A1 (en) * 2018-03-26 2021-03-18 Эмджен Инк. GENERAL AFUCOSYLATED ANTIBODY GLYCOFORM OBTAINED IN CELL CULTURE
CA3099757A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
CA3110254C (en) * 2018-08-29 2023-08-29 United Biopharma Inc Afucosylated antibodies and manufacture thereof
MA53603A (en) 2018-09-11 2021-07-21 Amgen Inc METHODS FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY MODULATION
HUP1800376A2 (en) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
EA202193029A1 (en) 2019-05-06 2022-03-17 Эмджен Инк. MODULATION OF THE EFFECTOR FUNCTIONS OF ANTIBODIES
CA3152623A1 (en) * 2019-10-11 2021-04-15 Richard D. Cummings Anti-tn antibodies and uses thereof
AR126089A1 (en) 2021-06-07 2023-09-13 Amgen Inc USE OF FUCOSIDASE TO CONTROL THE LEVEL OF AFFUCOSYLATION OF GLUCOSYLATED PROTEINS
WO2023015027A1 (en) * 2021-08-06 2023-02-09 Anyadi, Llc Process for producing personalized cancer immunotherapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
WO2000018938A1 (en) 1998-09-29 2000-04-06 Pioneer Hi-Bred International, Inc. Mar/sar elements flanking rsyn7-driven construct
KR100408844B1 (en) 2000-07-29 2003-12-06 한국산업기술평가원 Expression vector using for animal cell
US7259010B2 (en) 2000-12-15 2007-08-21 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region of interferon beta
ATE437233T1 (en) 2001-01-26 2009-08-15 Selexis Sa MATRIX ATTACHMENT REGIONS AND METHOD OF USE THEREOF
EP1443961B1 (en) * 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
EP1888638A2 (en) * 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
CL2007002926A1 (en) * 2006-10-12 2008-05-16 Genentech Inc ALFA ANTILINPHOTOXINE ANTIBODY (LT-ALFA); COMPOSITION WITH THE ANTIBODY; PTA-7538 HYBRIDOMA; NUCLEIC ACID CODIFYING THE ANTIBODY; VECTOR AND CELL GUEST UNDERSTANDING NUCLEIC ACID; METHOD FOR INHIBITING THE ACTIVATED CELL PROLIFERATION P
KR101441437B1 (en) * 2009-06-02 2014-09-25 리제너론 파마슈티칼스 인코포레이티드 Fucosylation-deficient cells
US20120277165A1 (en) * 2009-06-05 2012-11-01 Collins Brian E Methods of modulating fucosylation of glycoproteins
ES2687771T3 (en) * 2011-03-06 2018-10-29 Merck Serono Sa Cell lines with low level of fucose and its uses
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
PL3036320T3 (en) * 2013-08-19 2021-11-02 Biogen Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
WO2016075662A2 (en) * 2014-11-15 2016-05-19 Zumutor Biologics, Inc. Dna-binding domain, non-fucosylated and partially fucosylated proteins, and methods thereof
US11267899B2 (en) * 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein

Also Published As

Publication number Publication date
US20210214462A1 (en) 2021-07-15
US20180251572A1 (en) 2018-09-06
CN108431026A (en) 2018-08-21
ES2875274T3 (en) 2021-11-10
AU2016350732A1 (en) 2018-04-05
WO2017079165A1 (en) 2017-05-11
IL258161B1 (en) 2023-04-01
SG10202103875WA (en) 2021-06-29
IL258161A (en) 2018-05-31
JP2019505164A (en) 2019-02-28
CN108431026B (en) 2023-02-17
EP3371206B1 (en) 2021-04-14
MX2018004831A (en) 2018-08-01
US11802165B2 (en) 2023-10-31
CN116731147A (en) 2023-09-12
PL3371206T3 (en) 2021-09-27
BR112018007356A2 (en) 2018-10-23
KR20180068967A (en) 2018-06-22
JP6983772B2 (en) 2021-12-17
AU2022202460A1 (en) 2022-05-05
CA2999047A1 (en) 2017-05-11
IL258161B2 (en) 2023-08-01
EP3925970A1 (en) 2021-12-22
US10975168B2 (en) 2021-04-13
EP3371206A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
IL258161A (en) Methods of making fucosylated and afucosylated forms of a protein
IL249955A0 (en) Method of computational protein design
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
EP3190041A4 (en) Paddle board and manufacturing method therefor
SG11201700296YA (en) Biotechnological production of lnt, lnnt and the fucosylated derivatives thereof
IL252696A0 (en) Protein manufacture
EP3378053C0 (en) Simulated dissectible tissue
GB201617085D0 (en) Compare and delay instructions
EP2977588A4 (en) Supercharger manufacturing method and supercharger
GB2522923B (en) Insoles and production methods
GB201421894D0 (en) End fitting and method of manufacture
GB2553700B (en) A construction board and a method of manufacture
PT3398598T (en) Sulfonamide derivative and preparation method and use thereof
EP3197098A4 (en) Heartbeat cycle setting method and terminal
IL258369A (en) Modified lysosomal protein and production thereof
IL252712A0 (en) Method of protein manufacture
SG11201706586SA (en) Column-pile connecting method and connecting structure
TWI560003B (en) Anti-loosen screw manufacturing method and screw member produced thereby
AP2017009840A0 (en) Ready-to-use therapeutic foodstuff and production method therefor
HK1256714A1 (en) Methods of manufacturing therapeutic proteins
HK1259370A1 (en) Methods of making fucosylated and afucosylated forms of a protein
GB201522610D0 (en) Protein
GB201515337D0 (en) Protein Expression
GB201518638D0 (en) Implants and methods of manufacturing implants